Author: Crystalys Therapeutics

Crystalys Therapeutics Strengthens Board of Directors and Leadership Team as Dotinurad Advances Through Global Phase 3 Development

September 23, 2026
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

July 22, 2026

Crystalys Therapeutics Strengthens Board of Directors and Leadership Team as Dotinurad Advances Through Global Phase 3 Development